US Patent 11959081 Transthyretin (TTR) iRNA compositions and methods of use thereof
Patent 11959081 was granted and assigned to Alnylam Pharmaceuticals on April, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+31 properties)
Article (+551 characters)
US Patent 11959081 Transthyretin (TTR) iRNA compositions and methods of use thereof
Article
Patent abstract
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the transthyretin (TTR) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an TTR gene and to methods of preventing and treating an TTR-associated disorder, e.g., senile systemic amyloidosis (SSA), systemic familial amyloidosis, familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy (FAC), leptomeningeal/Central Nervous System (CNS) amyloidosis, and hyperthyroxinemia.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Adam Castoreno0
James D. McIninch0
Mark K. Schlegel0
Date of Patent
April 16, 2024
0Patent Application Number
179359970
Date Filed
September 28, 2022
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11959081 Transthyretin (TTR) iRNA compositions and methods of use thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
